Mineralys Therapeutics, Inc.
MLYSNASDAQHealthcare● Active
$22.50
$-1.19(-5.02%)
Market Cap$1.5B
P/E Ratio—
52W High$47.65
52W Low$12.59
Mineralys Therapeutics, Inc. (MLYS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MLYS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.13B | $0.17B | $0.07B | $0.03B | $0.02B |
| G&A Expenses | $0.04B | $0.02B | $0.01B | $0.01B | $0.00B |
| Total Operating Expenses | $0.17B | $0.19B | $0.08B | $0.03B | $0.02B |
| Operating Income | ($0.17B) | ($0.19B) | ($0.08B) | ($0.03B) | ($0.02B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.02B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.15B) | ($0.18B) | ($0.07B) | ($0.03B) | ($0.02B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.15B) | ($0.18B) | ($0.07B) | ($0.03B) | ($0.02B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.29 | $-3.66 | $-1.99 | $-5.77 | $-3.89 |
| Wtd Avg Shares | 0.07B | 0.05B | 0.04B | 0.01B | 0.00B |
| EBITDA | ($0.17B) | ($0.19B) | ($0.08B) | ($0.03B) | ($0.02B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Mineralys Therapeutics, Inc. data
About Mineralys Therapeutics, Inc. (MLYS) Income Statement
Mineralys Therapeutics, Inc. (MLYS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MLYS reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.15B) — a net profit margin of —.
Frequently asked questions
MLYS · 4 questionsMineralys Therapeutics, Inc. (MLYS) reported revenue of $0.00B for 2025, down —% year-over-year.
MLYS revenueMLYS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08